5-HT1 receptor agonists for the treatment of L-DOPA-induced dyskinesia: From animal models to clinical investigation

Basal Ganglia

Volumn 3, Issue 1, 2013, Pages 9-13

  Tronci, Elisabetta ^a   Carta, Manolo ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

5HT1 receptor agonists; 6 OHDA; Dopamine; Dyskinesia; L DOPA; Serotonin

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 5 PROPOXY 3 (1,2,5,6 TETRAHYDRO 4 PYRIDYL)PYRROLO[3,2 B]PYRIDINE; BUSPIRONE; DOPAMINE TRANSPORTER; ELTOPRAZINE; LEVODOPA; SARIZOTAN; SEROTONIN 1 AGONIST; SEROTONIN 1 RECEPTOR; SEROTONIN 1A RECEPTOR; SEROTONIN TRANSPORTER;

CELL DEGENERATION; CLINICAL TRIAL (TOPIC); DOPAMINE RELEASE; DRUG ANTAGONISM; DRUG EFFICACY; DRUG SAFETY; DYSKINESIA; EXPERIMENTAL MODEL; HUMAN; MOLECULAR PATHOLOGY; MOTOR DEPRESSION; MOTOR DYSFUNCTION; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RESTLESSNESS; REVIEW; SEROTONIN SYNDROME; SEROTONINERGIC SYSTEM; SYNAPTIC TRANSMISSION; UNSPECIFIED SIDE EFFECT;

EID: 84875408069     PISSN: 22105336     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.baga.2012.12.002     Document Type: Review

References (60)

1. Antonini A., Ursino G., Calandrella D., Bernardi L., Plebani M. Continuous dopaminergic delivery in Parkinson's disease. Journal of Neurology 2010, 257(Suppl. 2):S305-S308.
2. Bronstein J.M., Tagliati M., Alterman R.L., Lozano A.M., Volkmann J., Stefani A., et al. DeLong MR Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. Archives of Neurology 2011, 68:165.
3. Bracco F., Battaglia A., Chouza C., Dupont E., Gershanik O., Marti Masso J.F., et al. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa controlled study. CNS Drugs 2004, 18:733-746.
4. Rascol O., Brooks D.J., Korczyn A.D., De Deyn P.P., Clarke C.E., Lang A.E. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. New England Journal of Medicine 2000, 342:1484-1491.
5. Luginger E., Wenning G.K., Bosch S., Poewe W. Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease. Movement Disorders 2000, 15:873-878.
6. Crosby N.J., Deane K.H., Clarke C.E. Amantadine for dyskinesia in Parkinson's disease. Cochrane Database of Systematic Reviews 2003, 2. CD003467.
7. Sawada H., Oeda T., Kuno S., Nomoto M., Yamamoto K., Yamamoto M., et al. Amantadine for dyskinesias in Parkinson's disease: a randomized controlled trial. PLoS ONE 2010, 5:e15298. Amantadine Study Group.
8. Thomas A., Iacono D., Luciano A.L., et al. Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. Journal of Neurology, Neurosurgery, and Psychiatry 2004, 75:141-143.
9. Cenci M.A., Ohlin K.E., Rylander D. Plastic effects of L-DOPA treatment in the basal ganglia and their relevance to the development of dyskinesia. Parkinsonism & Related Disorders 2009, 15(Suppl. 3):S59-S63.
10. Brotchie J.A. Nondopaminergic mechanisms in levodopa-induced dyskinesia. Movement Disorders 2005, 20:919-931.
11. Cenci M.A. Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia. Trends in Neurosciences 2007, 30:236-243.
12. Jenner P. Molecular mechanisms of L-DOPA-induced dyskinesia. Nature Reviews Neuroscience 2008, 9:665-677.
13. Arai R., Karasawa N., Geffard M., Nagatsu I. L-DOPA is converted to dopamine in serotonergic fibers of the striatum of the rat: a doublelabeling immunofluorescence study. Neuroscience Letters 1995, 195:195-198.
14. Maeda T., Nagata K., Yoshida Y., Kannari K. Serotonergic hyperinnervation into the dopaminergic denervated striatum compensates for dopamine conversion from exogenously administered l-DOPA. Brain Research 2005, 1046:230-233.
15. de la Fuente-Fernández R., Sossi V., Huang Z., Furtado S., Lu J.Q., Calne D.B., et al. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain 2004, 127:2747-2754.
16. Carta M., Carlsson T., Kirik D., Bjorklund A. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in Parkinsonian rats. Brain 2007, 130:1819-1833.
17. Eskow K.L., Dupre K.B., Barnum C.J., Dickinson S.O., Park J.Y., Bishop C. The role of the dorsal raphe nucleus in the development, expression, and treatment of L-dopa-induced dyskinesia in hemiparkinsonian rats. Synapse 2009, 63:610-620.
18. Navailles S., Bioulac B., Gross C., De Deurwaerdère P. Serotonergic neurons mediate ectopic release of dopamine induced by L-DOPA in a rat model of Parkinson's disease. Neurobiology of Disease 2010, 38:136-143.
19. Kannari K., Tanaka H., Maeda T., Tomiyama M., Suda T., Matsunaga M. Reserpine pretreatment prevents increases in extracellular striatal dopamine following L-DOPA administration in rats with nigrostriatal denervation. Journal of Neurochemistry 2000, 74:263-269.
20. Everett G.M., Borcherding J.W. L-DOPA: effect on concentrations of dopamine, norepinephrine, and serotonin in brains of mice. Science 1970, 168:847-850.
21. Bézard E., Ferry S., Mach U., Stark H., Leriche L., Boraud T., et al. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nature Medicine 2003, 9:762-767.
22. Lundblad M., Andersson M., Winkler C., Kirik D., Wierup N., Cenci M.A. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. European Journal of Neuroscience 2002, 15:120-132.
23. Cenci M.A., Lundblad M. Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia. Journal of Neurochemistry 2006, 99:381-392.
24. Guigoni C., Doudnikoff E., Li Q., Bloch B., Bezard E. Altered D(1) dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates. Neurobiology of Disease 2007, 26:452-463.
25. Chase T.N., Oh J.D. Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications. Annals of Neurology 2000, 47:S122-S129. discussion S129-30.
26. Gardoni F., Picconi B., Ghiglieri V., Polli F., Bagetta V., Bernardi G., et al. A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia. Journal of Neuroscience 2006, 15:2914-2922.
27. Hallett P.J., Dunah A.W., Ravenscroft P., Zhou S., Bezard E., Crossman A.R., et al. Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Neuropharmacology 2005, 48:503-516.
28. Silverdale M.A., Kobylecki C., Hallett P.J., Li Q., Dunah A.W., Ravenscroft P., et al. Synaptic recruitment of AMPA glutamate receptor subunits in levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate. Synapse 2010, 64:177-180.
29. Ulusoy A., Sahin G., Kirik D. Presynaptic dopaminergic compartment determines the susceptibility to L-DOPA-induced dyskinesia in rats. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:13159-13164.
30. Chase T.N. Levodopa therapy: consequences of the nonphysiologic replacement of dopamine. Neurology 1998, 50(5 Suppl. 5):S17-S25.
31. Lee J., Zhu W.M., Stanic D., Finkelstein D.I., Horne M.H., Henderson J., et al. Sprouting of dopamine terminals and altered dopamine release and uptake in Parkinsonian dyskinaesia. Brain 2008, 131:1574-1587.
32. Troiano A.R., de la Fuente-Fernandez R., Sossi V., Schulzer M., Mak E., Ruth T.J., et al. PET demonstrates reduced dopamine transporter expression in PD with dyskinesias. Neurology 2009, 72:1211-1216.
33. Rylander D., Parent M., O'Sullivan S.S., Dovero S., Lees A.J., Bezard E., et al. Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. Annals of Neurology 2010, 68:619-628.
34. Muñoz A., Carlsson T., Tronci E., Kirik D., Björklund A., Carta M. Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model. Experimental Neurology 2009, 219:298-307.
35. Tanaka H., Kannari K., Maeda T., Tomiyama M., Suda T., Matsunaga M. Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. Neuroreport 1999, 10:631-634.
36. Bishop C., George J.A., Buchta W., Goldenberg A.A., Mohamed M., Dickinson S.O., et al. Eskow Jaunarajs KL. Serotonin transporter inhibition attenuates l-DOPA-induced dyskinesia without compromising l-DOPA efficacy in hemi-parkinsonian rats. European Journal of Neuroscience 2012, 36:2839-2848.
37. Chalmers D.T., Watson S.J. Comparative anatomical distribution of 5-HT1A receptor mRNA and 5-HT1A binding in rat brain - a combined in situ hybridisation/in vitro receptor autoradiographic study. Brain Research 1991, 561:51-60.
38. Riad M., Garcia S., Watkins K.C., Jodoin N., Doucet E., Langlois X., et al. Somatodendritic localization of 5-HT1A and preterminal axonal localization of 5-HT1B serotonin receptors in adult rat brain. Journal of Comparative Neurology 2000, 417:181-194.
39. Adell A., Celada P., Artigas F. The role of 5-HT1B receptors in the regulation of serotonin cell firing and release in the rat brain. Journal of Neurochemistry 2001, 79:172-182.
40. Sari Y., Miquel M.C., Brisorgueil M.J., Ruiz G., Doucet E., Hamon M., et al. Cellular and subcellular localization of 5-hydroxytryptamine1B receptors in the rat central nervous system: immunocytochemical, autoradiographic and lesion studies. Neuroscience 1999, 88:899-915.
41. Iravani M.M., Jackson M.J., Kuoppamaki M., Smith L.A., Jenner P. 3,4-methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates. Journal of Neuroscience 2003, 23:9107-9115.
42. Bishop C., Taylor J.L., Kuhn D.M., Eskow K.L., Park J.Y., Walker P.D. MDMA and fenfluramine reduce L-DOPA-induced dyskinesia via indirect 5-HT1A receptor stimulation. European Journal of Neuroscience 2006, 23:2669-2676.
43. Eskow K.L., Gupta V., Alam S., Park J.Y., Bishop C. The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves L-DOPA efficacy. Pharmacology Biochemistry and Behavior 2007, 87:306-314.
44. Dupre K.B., Ostock C.Y., Eskow Jaunarajs K.L., Button T., Savage L.M., Wolf W., et al. Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats. Experimental Neurology 2011, 229:288-299.
45. Zhang X., Andren P.E., Greengard P., Svenningsson P. Evidence for a role of the 5-HT1B receptor and its adaptor protein, p11, in L-DOPA treatment of an animal model of Parkinsonism. Proceedings of the National Academy of Sciences United States of America 2008, 105:2163-2168.
46. Carey R.J., Depalma G., Damianopoulos E., Muller C.P., Huston J.P. The 5-HT1A receptor and behavioral stimulation in the rat: effects of 8-OHDPAT on spontaneous and cocaine-induced behavior. Psychopharmacology (Berlin) 2004, 177:46-54.
47. Iravani M.M., Tayarani-Binazir K., Chu W.B., Jackson M.J., Jenner P. In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with increased motor disability. Journal of Pharmacology and Experimental Therapeutics 2006, 319:1225-1234.
48. Muñoz A., Li Q., Gardoni F., Marcello E., Qin C., Carlsson T., et al. Carta M. Combined 5-HT1A and 5- HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Brain 2008, 131:3380-3394.
49. Miczek K.A., Mos J. Olivier B. Brain 5-HT and inhibition of aggressive behavior in animals: 5-HIAA and receptor subtypes. Psychopharmacology Bulletin 1989, 25:399-403.
50. Mos J., Olivier B., Poth M., van Aken H. The effects of intraventricular administration of eltoprazine, 1-(3-trifluoromethylphenyl)piperazine hydrochloride and 8-hydroxy-2-(di-n-propylamino) tetralin on resident intruder aggression in the rat. European Journal of Pharmacology 1992, 212:295-298.
51. Bezard E, Tronci E, Pioli E, Li Q, Porras G, Björklund A, et al. Study of the antidyskinetic effect of eltoprazine in animal models of L-DOPAinduced dyskinesia. Movement Disorders, in press. doi:10.1002/mds.25366.
52. Hammerstad J.P., Carter J., Nutt J.G., Casten G.C., Shrotriya R.C., Alms D.R., et al. Buspirone in Parkinson's disease. Clinical Neuropharmacology 1986, 9:556-560.
53. Bonifati V., Fabrizio E., Cipriani R., Vanacore N., Meco G. Buspirone in levodopa-induced dyskinesias. Clinical Neuropharmacology 1994, 17:73-82.
54. Kleedorfer B., Lees A.J., Stern G.M. Buspirone in the treatment of levodopa induced dyskinesias. Journal of Neurology, Neurosurgery, and Psychiatry 1991, 54:376-377.
55. Bibbiani F., Oh J.D., Chase T.N. Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology 2001, 57:1829-1834.
56. Bara-Jimenez W., Bibbiani F., Morris M.J., Dimitrova T., Sherzai A., Mouradian M.M., et al. Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease. Movement Disorders 2005, 20:932-936.
57. Olanow C.W., Damier P., Goetz C.G., Mueller T., Nutt J., Rascol O., et al. Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study). Clinical Neuropharmacology 2004, 27:58-62.
58. Goetz C.G., Damier P., Hicking C., Laska E., Müller T., Olanow C.W., et al. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Movement Disorders 2007, 22:179-186.
59. Bartoszyk G.D., Van Amsterdam C., Greiner H.E., Rautenberg W., Russ H., Sarizotan Seyfried C.A. a serotonin 5-HT1a receptor agonist and dopamine receptor ligand. 1. Neurochemical profile. Journal of Neural Transmission 2004, 111:113-126.
60. Rijnders H.J., Slangen J.L. The discriminative stimulus properties of buspirone involve dopamine-2 receptor antagonist activity. Psychopharmacology (Berlin) 1993, 111:55-61.